What is Beechtree Diagnostics?
Beechtree Diagnostics is a provider of customizable laboratory testing solutions, primarily serving medical professionals across various specialties. The company's core offerings include urine toxicology testing, blood testing, molecular diagnostics, and pharmacogenomics (PGX) testing. These services are crucial for fields such as addiction treatment, psychiatric care, obstetrics, primary care, pain management, and employee health programs. By delivering high-quality lab services, Beechtree Diagnostics aims to enhance patient care and support healthcare providers in making informed clinical decisions.
How much funding has Beechtree Diagnostics raised?
Beechtree Diagnostics has raised a total of $859K across 2 funding rounds:
Debt
$350K
Debt
$509K
Debt (2020): $350K with participation from PPP
Debt (2021): $509K led by PPP
Key Investors in Beechtree Diagnostics
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Beechtree Diagnostics?
The recent major strategic investment signals a pivotal moment for Beechtree Diagnostics, likely enabling expansion of its service offerings, enhancement of its technological infrastructure, and broader market penetration. This capital infusion is expected to fuel further innovation in diagnostic capabilities and solidify its position as a key player in the specialized lab testing market. The company's focus on tailored solutions for medical professionals suggests a strategic direction towards deepening client relationships and adapting to evolving healthcare needs.
See full Beechtree Diagnostics company page
